Clinical Trials on ET (Essential Thrombocythemia)

Total 975 results

M.D. Anderson Cancer Center
Celgene

Completed

Pomalidomide for Myelofibrosis Patients

Polycythemia Vera | Thrombocythemia

United States
Novartis Pharmaceuticals

Completed

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Bone Marrow Diseases | Hematologic Diseases | Blood Coagulation Disorders | Hemorrhagic Disorders | Primary Myelofibrosis | Myeloproliferative Disorders | Polycythemia Vera | Thrombocytosis | Essential Thrombocythemia | Blood Platelet Disorders

United Kingdom, Belgium, Canada, France, Australia, Netherlands, Spain, Denmark, Ireland, Italy, Germany
Eli Lilly and Company

Completed

A Study in Myeloproliferative Disorders

Primary Myelofibrosis | Myeloproliferative Disorders | Polycythemia Vera | Thrombocythemia, Essential

United States
Novartis Pharmaceuticals
Incyte Corporation

Terminated

A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis

Myelofibrosis

Spain, United Kingdom, Australia, Israel, Germany, Italy, Singapore, Austria, France
Exelixis

Terminated

A Safety Study of XL019 in Adults With Myelofibrosis

Myeloproliferative Disorders | Polycythemia Vera | Thrombocythemia, Essential | Myelofibrosis

United States
Baxalta now part of Shire
CTI BioPharma

Withdrawn

A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis

Primary Myelofibrosis
Novartis Pharmaceuticals

Completed

Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial

Myelofibrosis

France, United Kingdom, Belgium, Germany, Netherlands, Italy, Austria, Spain, Sweden
Galena Biopharma, Inc.

Completed

A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders

Thrombocytosis | Myeloproliferative Neoplasms

United States
M.D. Anderson Cancer Center
Active Biotech AB

Not yet recruiting

Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-Essential Thrombocytosis Myelofibrosis

United States
Cephalon

Completed

Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis

Polycythemia Vera | Essential Thrombocytosis

United States
University of Utah
National Cancer Institute (NCI)

Terminated

CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia

Obstructive Sleep Apnea Syndrome | Polycythemia Vera | Essential Thrombocythemia | CALR Gene Mutation | JAK2 Gene Mutation | MPL Gene Mutation

United States
TargeGen

Completed

A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis

Myelofibrosis

United States
University of Southern Denmark

Unknown

Myeloproliferative Neoplasms and Bone Structure

Primary Myelofibrosis | Polycythemia Vera | Thrombocythemia, Essential

Denmark
Nanfang Hospital, Southern Medical University

Recruiting

The Role of Circ0014614 in the Formation and Development of ET

Primary Thrombocytosis

China
GE Healthcare

Completed

Multi-site Anesthesia Randomized Controlled STudy of End Tidal Control Compared to Conventional Anesthesia Results

Et Control Performance in Adult Population Surgery

United States
M.D. Anderson Cancer Center
S*BIO

Completed

Study of SB939 in Subjects With Myelofibrosis

Myeloproliferative Disorders

United States
Northwestern University
National Cancer Institute (NCI); Celgene; The Leukemia and Lymphoma Society

Withdrawn

Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase

United States
National Institutes of Health Clinical Center (CC)

Completed

Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders

Polycythemia Vera | Chronic Myeloproliferative Disorders | Essential Thrombocytosis | Idiopathic Myelofibrosis | Neutrophils

United States
Dr Adolf Lukanovič
Juna d.o.o.

Unknown

Nd:Yttrium Aluminum Garnet Laser Treatment for Lichen Sclerosus

Lichen Sclerosus | Lichen Sclerosus Et Atrophicus
University Hospital Inselspital, Berne
Deka Medical, Inc.

Active, not recruiting

Effect of Treatment With the Ablative Fractional Carbodioxide Laser in Vulvar Lichen Sclerosis

Lichen Sclerosus Et Atrophicus of the Vulva

Switzerland
University of Washington

Recruiting

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Acute Myeloid Leukemia | Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm | Secondary Myelofibrosis | Myeloproliferative Neoplasm, Unclassifiable

United States
Medical University of Graz

Recruiting

Laser Therapy in Women With Lichenoid Disorders (Liser)

Lichen Planus | Lichen Sclerosus Et Atrophicus

Austria
Incyte Corporation

Completed

COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

MPN (Myeloproliferative Neoplasms)

United States, Canada, Australia
Incyte Corporation

Completed

An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis

MPN (Myeloproliferative Neoplasms)

Canada, United States, Australia
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Novartis Pharmaceuticals

Completed

LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

CC-4047 in Treating Patients With Myelofibrosis

Chronic Myeloproliferative Disorders | Secondary Myelofibrosis

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Childhood Acute Myeloid Leukemia and other conditions

United States
University Health Network, Toronto

Recruiting

Myeloproliferative Neoplasms (MPNs) Patient Registry

Neoplasms | Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Leukemia, Myelomonocytic, Chronic | Leukemia, Myelomonocytic, Juvenile | Myelodysplastic-Myeloproliferative Diseases | Mastocytosis | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | Chronic Eosinophilic Leukemia-not...

Canada
ShangHai Ji Ai Genetics & IVF Institute

Withdrawn

Comparing Radiological Tubal Blockage Versus Laparoscopic Salpingectomy in Infertile Women With Hydrosalpinx During in Vitro Fertilization Treatment

Hydrosalpinx | IVF-ET

China
Universidade Federal de Santa Maria

Completed

Effects of TENS and IES on the Autonomous Balance of Normotens Volunteers and Hypertensive Patients

Healthy Volunteers | Hypertension, Essential

Brazil
Addpharma Inc.

Completed

A Study to Evaluate the Efficacy and Safety of AD-209

Hypertension, Essential

Korea, Republic of
Bayer

Completed

Single Dose Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions

Hypertension, Essential

Germany
National Cancer Institute (NCI)

Active, not recruiting

Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

Acute Myeloid Leukemia | Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic/Myeloproliferative... and other conditions

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies

Polycythemia Vera | Essential Thrombocythemia | Chronic Myeloproliferative Disorders | Multiple Myeloma | Myelofibrosis | Chronic Myelomonocytic Leukemia | Chronic Lymphocytic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Prolymphocytic Leukemia | Plasma Cell Leukemia | Small Lymphocytic Lymphoma and other conditions

United States
Cytos Biotechnology AG

Completed

Safety, Tolerability and Efficacy of a Vaccine Against Essential Hypertension

Mild Essential Hypertension | Moderate Essential Hypertension

Switzerland
Sulaiman AlRajhi Colleges

Unknown

The Association Between Serum β-hydroxybutyrate and Levels of Systemic Hypertension (BHB-RCT)

Hypertension, Essential | β-hydroxybutyrate
Bayer

Completed

Pivotal Bioequivalence FDC Nifedipine / Candesartan vs. Loose Combination of Single Components, Fed

Hypertension, Essential

Germany
Thomas Jefferson University

Recruiting

Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myeloid Leukemia | Polycythemia Vera | Essential Thrombocythemia | Hodgkin Lymphoma | Myelofibrosis | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma and other conditions

United States
Constellation Pharmaceuticals
The Leukemia and Lymphoma Society

Active, not recruiting

A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis

Neoplasms | Neoplasms by Histologic Type | Leukemia | Preleukemia | Primary Myelofibrosis | Myeloproliferative Disorders | Myelofibrosis | Precancerous Conditions | Myelodysplastic/Myeloproliferative Neoplasm | Myelodysplastic Syndrome (MDS) | Leukemia, Myelocytic, Acute | Bone Marrow Disease | Hematological Disease and other conditions

Canada, United States, United Kingdom, Germany, Italy, Belgium, France, Netherlands, Poland
Stanford University

Completed

Management of Palmar Hyperhidrosis With Hydrogel-based Iontophoresis

Hyperhidrosis | Hyperhidrosis Palmaris et Plantaris

United States
Addpharma Inc.

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of AD-224

Hypertension,Essential
Instituto de Cardiologia do Rio Grande do Sul

Recruiting

Effect of Isometric and Aerobic Physical Exercise on Blood Pressure Levels in Hypertensive Elderly People

Hypertension | Hypertension,Essential

Brazil
Federal University of Health Science of Porto Alegre
Irmandade Santa Casa de Misericórdia de Porto Alegre; Leonhardt Ventures LLC

Not yet recruiting

Effects of Electrical Nervous Stimulation Transcutaneous in Hypertensive Patients

Hypertension | Hypertension,Essential
Linkoeping University

Recruiting

Licorice and Home Blood Pressure, Additional Study

Hypertension,Essential

Sweden
Brainfarma Industria Química e Farmacêutica S/A

Not yet recruiting

Efficacy and Safety Study of the Fixed-dose Combination of Olmesartan + Indapamide When Compared to the Isolated Drugs in the Treatment of Hypertension. (OLINDA)

Hypertension | Hypertension,Essential
Penn State University
National Heart, Lung, and Blood Institute (NHLBI)

Terminated

Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvessels in Humans (H2SPharm)

Hypertension,Essential

United States
Vanderbilt University

Terminated

Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension

Hypertension | Hypertension, Essential

United States
The Hong Kong Polytechnic University

Unknown

Hypertension Treatment Adherence Improving Trial

Hypertension,Essential

China, Hong Kong
Addpharma Inc.

Completed

Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension

Hypertension,Essential

Korea, Republic of
Stendhal Americas, S.A.

Completed

Efficacy and Safety of Fimasartan Alone or Combined With HCTZ in Mexican Patients With Essential Hypertension (FIRME-1)

Hypertension, Essential

Mexico

Clinical Trials on ET (Essential Thrombocythemia)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations